Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer

BACKGROUND: Pancreatic cancer retains a poor prognosis among the gastrointestinal cancers. It affects 230,000 individuals worldwide, has a very high mortality rate, and remains one of the most challenging malignancies to treat successfully. Treatment with gemcitabine, the most widely used chemothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Azorsa, David O, Gonzales, Irma M, Basu, Gargi D, Choudhary, Ashish, Arora, Shilpi, Bisanz, Kristen M, Kiefer, Jeffrey A, Henderson, Meredith C, Trent, Jeffrey M, Von Hoff, Daniel D, Mousses, Spyro
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702280/
https://www.ncbi.nlm.nih.gov/pubmed/19519883
http://dx.doi.org/10.1186/1479-5876-7-43

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702280/
https://www.ncbi.nlm.nih.gov/pubmed/19519883
http://dx.doi.org/10.1186/1479-5876-7-43

Ejemplares similares